Brentuximab vedotin is an antibody-drug conjugate (ADC) used in targeted immunotherapy. The monoclonal antibody component binds to the cell surface protein CD30, which is normally present on activated B and T lymphocytes but is overexpressed in several lymphomas, making CD30 an important therapeutic target. The FDA has approved brentuximab vedotin for multiple different types and stages of cancer, including classical Hodgkin lymphoma (cHL), anaplastic large cell lymphoma (ALCL), and select peripheral T-cell lymphomas.
Granger Genetics now offers a clinically validated anti-drug antibody (ADA) assay to monitor immune responses against brentuximab vedotin.
Since Brentuximab vedotin is used across diverse patient populations, monitoring for anti-drug antibodies is essential. The presence of these antibodies has been associated with infusion-related reactions, and their impact on drug efficacy remains unclear. Our Brentuximab ADA assay enables early detection of anti-drug antibodies, supporting proactive treatment decisions and personalized patient management.
What is Brentuximab?
Brentuximab vedotin (BTX) is an immunotherapeutic drug composed of three components: an IgG1 monoclonal antibody that targets CD30, a protease-cleavable linker, and a cytotoxic payload. In theory, any of these components could elicit an immune response; however, studies have shown that most anti-BTX antibodies are directed against the antibody portion of the molecule. In sponsor clinical trials, approximately 60% of patients who developed antibodies were found to have neutralizing antibodies. Routine ADA testing helps identify patients at risk of reduced therapeutic response, supporting proactive management and individualized care.The Testing
While Brentuximab is a highly effective therapy, it is foreign to the human immune system. The use of Brentuximab can provoke an immunogenic response, leading to the development of anti-drug antibodies (ADAs). These anti-Brentuximab antibodies may neutralize Brentuximab or alter its pharmacokinetics, potentially reducing its efficacy in subsequent treatments.
How Does It Work?
A minimum of 0.200 mL of serum is needed to perform the assay. The presence or absence of antibodies is determined through a traditional antigen-capture ELISA assay. Brentuximab is used as the antigen for coating the plate in which the antibodies are then immobilized. Bound antibodies are detected with an HRP-conjugated detection antibody and TMB enzyme substrate.